Coalition for Epidemic Preparedness Innovations (CEPI) and Gennova Biopharmaceuticals Ltd from Pune have announced an updated funding agreement to expedite the advancement of their self-amplifying mRNA (saRNA) platform for generating vaccine candidates against unknown pathological threats, referred to as Disease X. 

CEPI will provide up to $3.6 million to optimize the saRNA-platform technology, manufacturing processes, and production output. 

The upcoming focus will involve the creation of a vaccine candidate targeting the rabies virus, which will then undergo preclinical assessments. 

The funding forms a part of CEPI's initiative to back pioneering RNA vaccine platform technologies designed for emerging infectious diseases and specific prevalent conditions. 

These methods may provide significant advantages over traditional mRNA procedures, including multivalency, greater immunogenicity, upgraded storage and stability, higher yield, quicker response times, and cost-efficiency. 

The saRNA vaccine platform created by Gennova might be one of the CEPI-endorsed RNA technology lineups that could enable rapid responses to future epidemics and pandemic dangers, possibly within 100 days of identification.